Carla Maria Canuso
Vice President, Head of Neuropsychiatry Clinical Development at Janssen Research & Development, LLC
Data updated
Papers
Trials
Research Footprint
Carla Maria Canuso appears in 7 tracked papers (2020–2026), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Safety & Risk Management.
Most-cited paper: Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) (407 citations).
Frequent co-authors: Daniel Fu, Robert Lane and William Drevets.
Background & Research
Carla M. Canuso, M.D. is a psychiatrist and drug-development leader at Janssen Research & Development. Her CV lists her current role as Vice President, Head of Neuropsychiatry Clinical Development, and her prior work leading the SPRAVATO (esketamine) development program for treatment-resistant depression and major depression with suicidal ideation. She earned her M.D. from the Medical College of Pennsylvania and completed psychiatry residency at the University of Chicago, followed by fellowship training in schizophrenia research.
Key Impact
She is a leading industry psychiatrist who helped drive clinical development of esketamine for treatment-resistant depression and suicidal ideation, shaping a major modern psychedelic-adjacent psychiatric treatment program.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Carla Maria Canuso is associated with.